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Design: Systematic review and meta-analysis.
Setting: Not applicable.
Patient(s): Infertile women with history of recurrent implantation failure, deﬁned as two or more failed ETs, undergoing one or more
IVF cycle(s).
Intervention(s): The review was registered in PROSPERO (CRD42017062494) before the start of the literature search. Observational
studies were identiﬁed by searching electronic databases. The following comparators were included: women with CE receiving antibi-
otics vs. untreated controls; women with cured CE vs. women with persistent CE; and women with cured CE vs. women with normal
endometrial histology (negative for CE). The summary measures were reported as odds ratio (OR) with 95% conﬁdence interval (CI).
Main Outcome Measure(s): Clinical pregnancy rate (CPR), ongoing pregnancy rate/live birth rate (OPR/LBR), implantation rate (IR),
miscarriage rate.
Result(s): A total of 796 patients (from ﬁve studies) were included. Women receiving antibiotic therapy (without the histologic conﬁr-
mation of CE cure) did not show any advantage in comparison with untreated controls (OPR/LBR, CPR, and IR). Patients with cured CE
showed higher OPR/LBR (OR 6.81), CPR (OR 4.02), and IR (OR 3.24) in comparison with patients with persistent CE. In vitro fertilization
outcome was comparable between women with cured CE and those without CE (OPR/LBR, CPR, and IR). Miscarriage rate was not signif-
icantly different between groups.
Conclusion(s): Chronic endometritis therapy may improve IVF outcome in patients suffering from recurrent implantation failure. A
control biopsy should always conﬁrm CE resolution before proceeding with IVF. (Fertil Steril 2018;110:103–12. 2018 by American
Society for Reproductive Medicine.)
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C hronic endometritis (CE) is a chronic infectious diseasecharacterized by a persistent inﬂammation of theendometrial lining, whose prevalence in the general
population is still unclear. Women with intrauterine pathol-
ogies, such as submucosal uterine ﬁbroids and endometrial
hyperplasia, were recently showed to be at higher risk of
suffering from CE (1, 2).
Chronic endometritis has subtle symptomatology, such as
dysfunctional uterine bleeding, pelvic discomfort, and
leukorrhea. For this reason it is often overlooked in clinical
practice (3, 4).
The diagnostic gold standard for CE is endometrial biopsy
with histologic analysis, in which the detection of endome-
trial stromal plasma cells represents the histologic diagnostic
marker (1–4).
Different authors have recently demonstrated that CE is
highly prevalent in infertile women, especially in those
with recurrent implantation failure (RIF) at IVF (5–7).
Interestingly, speciﬁc antibiotics (against Gram-negative or
intracellular bacteria) can cure CE in the majority of
patients (cure rate up to 80% after a single antibiotic cycle)
(7). Nevertheless, it is still unclear whether CE cure results in
a better chance to achieve clinical pregnancy and live birth
in subsequent IVF-ET attempts (7, 8).
Thus, the aim of the present study was to summarize the
evidence regarding the impact of CE treatment on IVF
outcome in women with a history of RIF.
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONMATERIALS AND METHODS
Study Design
This was a systematic review of published and unpublished
data. The study protocol was registered in PROSPERO (in
the context of a review project entitled ‘‘Systematic review
and meta-analysis of prevalence and reproductive implica-
tions of chronic endometritis in women affected by infertility
or recurrent pregnancy loss,’’ CRD42017062494). Review was
reported according to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses guidelines (9).Ethical Approval
Because this study was a systematic review and meta-anal-
ysis, formal ethical approval was not required.Search Strategy
Electronic databases (ScienceDirect, MEDLINE, Scopus, Em-
base, the Cochrane Library, Clinicaltrials.gov, EU Clinical Tri-
als Register, and the World Health Organization International
Clinical Trials Registry) were searched until November 8, 2017
(without date restriction).
Key search terms were as follows: chronic endometritis
OR endometrial inﬂammation OR endometrial plasma cells
OR antibiotic therapy AND IVF OR ICSI OR embryo transfer
OR embryo implantation AND failure OR impairment OR
defect OR deﬁciency. The electronic search and the eligibility
of the studies were independently assessed by two of the au-
thors (A.V. and M.N.).104Inclusion Criteria
We included all studies evaluating the effects of CE therapy
on IVF-ET outcome in patients with RIF (deﬁned as at least
two previous failed IVF-ET attempts). All studies (experi-
mental and observational) reported in the English language
were eligible. Chronic endometritis was deﬁned as the histo-
logic presence (demonstrated by conventional staining and/
or by immunohistochemistry) of at least one endometrial
stromal plasma cell in the entire section. Studies evaluating
other types of endometrial inﬂammation (such as acute, sub-
acute, or tubercular endometritis) were excluded.
Comparators. Comparators were as follows. [1] Patients with
treated CE vs. untreated CE: deﬁned as patients receiving
antibiotic therapy for CE vs. patients with CE not receiving
antibiotics. Control biopsy was not performed. [2] Patients
with cured CE vs. persistent CE: deﬁned as patients in
whom (after antibiotic therapy) a control biopsy showed the
resolution of CE vs. those in which CE was still present. [3] Pa-
tients with cured CE vs. non-CE: deﬁned as women with CE
resolution (after antibiotic therapy) vs. women negative for
CE (with normal endometrial histology).
Outcomes. Outcomes were ongoing pregnancy or live birth
rate (per patient [OPR/LBR]): ‘‘ongoing pregnancy’’ deﬁned
as a pregnancy beyond 12 weeks' gestation, ‘‘live birth’’
deﬁned as the delivery of one or more living infants; clinical
pregnancy rate (per patient [CPR]): deﬁned as the presence of
a gestational sac on transvaginal ultrasound or other deﬁni-
tive clinical signs; implantation rate (per embyo [IR]): deﬁned
as the number of gestational sacs on transvaginal ultrasound
divided by the number of embryos transferred; and miscar-
riage rate (per clinical pregnancy [MR]): deﬁned as fetal loss
before the 20 weeks' gestation.Study Selection and Data Extraction
Two authors (A.V. and M.N.) independently assessed the in-
clusion criteria and study selection. Disagreements were dis-
cussed with a third reviewer (C.S.).
Data extraction was performed by two independent in-
vestigators (A.V. and C.S.). When studies involved a control
group considered negligible for the endpoints of the meta-
analysis, authors provided only a qualitative data extraction.
A manual search of reference lists of studies was performed to
avoid missing relevant publications. One author (A.D.S.S.) re-
viewed the selection and data extraction process. The results
were then compared and any disagreement discussed and
resolved by consensus. Additional data and details about
included studies were obtained by contacting study authors
by e-mail.Risk of Bias
Two reviewers (A.V. and M.N.) independently judged the
methodological quality of studies included in the meta-
analysis using a modiﬁed version of the ‘‘Newcastle-Ottawa
Scale’’ (10). Quality of studies was evaluated in ﬁve different
domains: ‘‘sample representativeness,’’ ‘‘sampling technique,’’
‘‘ascertainment of chronic endometritis diagnosis,’’ ‘‘qualityVOL. 110 NO. 1 / JULY 2018
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data’’ (Supplemental Table 1, available online). According to
the total number of points assigned, each study was judged
to be at low risk of bias (R3 points) or high risk of bias (<3
points). Any discrepancies concerning authors' judgements
were referred to a third reviewer (A.D.S.S.) and resolved by
consensus.Statistical Analysis and Publication Bias
Assessment
Data analysis was performed independently by two authors
(A.V. and C.S.) with Review Manager version 5.3 (Nordic Co-
chrane Centre, Cochrane Collaboration). All results were
compared, and any differences were discussed. Study out-
comes were expressed using odds ratio (OR) with 95% conﬁ-
dence interval (95% CI). A P value of < .05 was considered
statistically signiﬁcant. Higgins I2 was used to assess hetero-
geneity (deﬁned as high when I2 wasR50% and low when I2
was <50%). When heterogeneity was high, we evaluated
‘‘random’’ outcomes. Subgroup and sensitivity analyses
were also planned to explore the sources of inconsistency
among studies (when at least three studies were included in
meta-analysis).
We followed Cochrane Handbook recommendations for
the assessment of publication bias (Cochrane Handbook,
10.4.3.1, ‘‘Recommendations on testing for funnel plot asym-
metry’’). However, not enough studies (fewer than ten) were
included in the pooled analysis.RESULTS
Study Selection
After the evaluation of full text, 12 studies were excluded
(8, 11–21) (characteristics of studies and reasons for
exclusion are reported in Supplemental Table 2). Finally, a
total of ﬁve studies (22–26) were included in the present
meta-analysis (Supplemental Fig. 1).Included Studies
The studies included a total number of 796 patients. All studies
were observational (three prospective (23, 25, 26) and two
retrospective (22, 24) studies). Yang et al. (23) reported two
different studies in their article (with prospective and
retrospective design, respectively). The retrospective one
(investigating the prevalence of CE in 60 patients, of whom
30 got pregnant and 30 did not) was excluded. In addition, a
group of patients from the Johnston-MacAnanny et al. study
(22) (in which CE was not investigated) was excluded.
Two studies compared patients with cured CE vs. patients
with persistent CE. Three studies included patients with cured
CE and patients not affected by CE. Yang et al. (23) compared
patients receiving antibiotic therapy for CE vs. patients not
receiving therapy for CE. Characteristics of included studies
are summarized in Table 1.
Patients. All trials included patients with RIF. Recurrent im-
plantation failure was deﬁned as the failure of at least two
(22, 25) or three (23, 24, 26) previous (fresh or frozen–VOL. 110 NO. 1 / JULY 2018thawed) IVF-ET attempts, including at least one good-
quality cleavage-stage embryo or blastocyst transferred per
cycle. Patients had heterogeneous causes of infertility (i.e.,
male factor, tubal factor, diminished ovarian reserve), except
in the Cicinelli et al. study (24) (which included only patients
with unexplained infertility).
IVF-ET cycle. All patients underwent homologous IVF-ET
cycles, except in the study by Tersoglio et al. (25) (oocyte
donation program). Three studies evaluated a single IVF-ET
attempt (23–25), whereas other studies evaluated two or
fewer (22) or three or fewer (26) IVF-ET cycles.
Only three studies reported adequate information about
IVF-ET protocols (22, 24, 25). Ovarian stimulation was
performed through the daily administration of recombinant
FSH alone (24) or in combination with hMG, using GnRH
antagonist (ﬁxed or ﬂexible protocol) or GnRH agonist (long
protocol) for pituitary desensitization. Urinary hCG (5,000–
10,000 IU) was administered when at least two preovulatory
(17-mm) follicles were identiﬁed on transvaginal ultrasound
scan. Egg retrieval was performed 34–35 hours after
ovulation induction, and no more than three (22–24, 26)
embryos or two blastocysts (25, 26) per cycle were
transferred. Speciﬁcally, in two studies (22, 24) only
cleavage-stage embryos (up to three) were transferred, whereas
in the study by Tersoglio et al. (25) only blastocysts (up to two)
were transferred. In another study (26), embryo transfer was
performed at cleavage stage or blastocyst stage (up to two blas-
tocysts or three cleavage-stage embryos transferred). No data
were available on embryo stage for the study by Yang et al.
(23). Preimplantation genetic testingwas not used (information
not available about two studies (23, 25)). Vaginal P was
administered (22, 24, 25) from the day of ET. In the study by
Tersoglio et al. (25), recipient preparation was achieved with
oral E2 valerate (and GnRH agonist depot for pituitary block).
Diagnosis of chronic endometritis. Plasma cells identiﬁca-
tion was achieved with hematoxilin and eosin staining alone
(24, 25) or in combination with immunohistochemical
examination for CD-138 (22, 23, 26) and CD-38 (23). Endo-
metrial specimens were collected during the follicular phase,
except in the Tersoglio et al. study (25) (day LHþ5). The diag-
nosis of CE was made by a single expert pathologist in three
studies (22, 24, 26). No information was obtained about two
studies (23, 25).
Therapy of chronic endometritis. First-line antibiotic therapy
for CE was germ-speciﬁc (when endometrial culture was per-
formed (24, 25) or empiric (doxycycline 200 mg/d for
14 days (22, 26), 1 g/d ciproﬂoxacin and metronidazole for
14 days (23)). In all studies, except Yang et al (23), a control
biopsy was performed to evaluate the rate of cure.Assessment of the Risk of Study Bias
Sample representativeness. Only two studies (24, 26) were
judged at low risk of bias for sample representativeness.
Other studies were judged at high risk of bias.
Sampling technique. Two studies (23, 26) had adequate
sampling strategy (random or consecutive). Other studies
did not provide data.105
TABLE 1
General features of the included studies.
Authors and year (reference)
Study design, country,
and time of realization
Participants and main
inclusion criteria IVF-ET cycle Methods Groups Outcomes
Johnston-MacAnanny et al. 2010
(22)
Retrospective study,
United States,
January 2001–
December 2007
518 patients undergoing up to two
IVF-ET cycles
At least two failed IVF-ET cycles
(withR1 good-quality embryo
transferred per cycle)
Normal karyotypes
Negative testing for
antiphospholipid antibodies
Normal uterine cavity
Short GnRH-ant or long
GnRH-a protocol
rFSH alone or rFSH plus
hMG
U-hCG (5,000–10,000
UI) at follicle size
17 mm (R2)
Egg retrieval 35 h after
ovulation induction
Luteal phase support
with 50 mg IM P
EB
HIS examination
Antibiotic therapy (if
necessary)
Control EB (if necessary)
IVF cycle
Group A: patients
with cured CE
(n ¼ 10)
Group B: patients
without CE
(n ¼ 23)
Clinical
pregnancy
rate
Miscarriage rate
Live birth rate
Yang et al. 2014 (23) Prospective cohort study,
China, May 2010–
April 2012
202 patients undergoing IVF-ET
cycle
Three failed IVF-ET cycles orR6
high-quality embryo transferred
Normal uterine cavity
– Diagnostic HSC
EB
HIS examination
Antibiotic therapy (when
appropriate)
IVF cycle
Group A: patients
with treated
CE (n ¼ 68)
Group B: patients
with
untreated CE
(n ¼ 20)
Clinical
pregnancy
rate
Ongoing
pregnancy/
live birth rate
Miscarriage rate
Cicinelli et al. 2015 (24) Retrospective study, Italy,
January 2009–June
2012
106 patients undergoing IVF-ET
cycle
Unexplained infertility
Age <40 y
At least 6 good-quality embryos
transferred inR3 previous IVF/
ICSI cycles
Normal karyotype
FSH on day 3%10 mUI/mL
BMI%30 kg/m2
No previous surgery for myoma and/
or endometriosis
No condition interfering with
immune system
No antiphospholipid syndrome or
thrombophilic condition
No antisperm antibodies
GnRH-ant with ﬂexible or
ﬁxed scheme
rFSH (175–225 IU/d)
U-hCG (10,000 IU) at
follicle size 17 mm
(R2)
Egg retrieval 34 h after
ovulation induction
%3 embryos transferred
(of which at least one
with good quality)
Luteal phase support
with vaginal P
Diagnostic HSC
EB
HIS examination
Endometrial culture
Antibiotic therapy (if
necessary)
Control EB
IVF cycle
Group A: patients
with cured CE
(n ¼ 46)
Group B: patients
with
persistent CE
(n ¼ 15)
Clinical
pregnancy
rate
Ongoing
pregnancy/
live birth rate
Miscarriage rate
Tersoglio et al. 2015 (25) Prospective cohort study,
Argentina, 2010–
2013
30 patients undergoing one
heterologous IVF-ET cycle
At least two IVF-ET cycles failed with
two or more blastocysts
transferred
No uterine malformation
No autoimmune thyroid disease
No antiphospholipid syndrome
Normal uterine cavity
Good embryo quality
Recipient preparation
with GnRH-a depot
and oral E2 valerate
EB
HIS examination
Flow cytometry
Endometrial culture
Antibiotic treatment
Control EB
OD cycle
Group A: patients
with cured CE
(n ¼ 9)
Group B: patients
with
persistent CE
(n ¼ 5)
Group C: patients
without CE
(n ¼ 16)
Clinical
pregnancy
rate
Ongoing
pregnancy/
live birth rate
Miscarriage rate
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TABLE 2
Authors' judgement of study quality according to the ‘‘Modiﬁed Newcastle-Ottawa Risk of Bias Scoring System.’’
Authors and year (reference)
Sample
representativeness
Sampling
technique
Ascertainment of
CE diagnosis
Quality of description
of the population
Incomplete
outcome data
Total
score
Risk of
bias
Johnston-MacAnanny et al.
2010 (22)
– – + + + +++ Low
Yang et al. 2014 (23) – + + – – ++ High
Cicinelli et al. 2015 (24) + – + + + ++++ Low
Tersoglio et al. 2015 (25) – – – + + ++ High
Kitaya et al. 2017 (26) + + + – + ++++ Low
Vitagliano. Antibiotics for chr endometritis. Fertil Steril 2018.
TABLE 1
Continued.
Authors and year (reference)
Study design, country,
and time of realization
Participants and main
inclusion criteria IVF-ET cycle Methods Groups Outcomes
Kitaya et al. 2017 (26)
[UMIN-CTR000006536]a
Prospective cohort study,
Japan, November
2011–July 2014
421 patients undergoing up to three
IVF-ET cycles
IVF failure with three or more
morphologically good cleavage-
stage embryos and/or
blastocysts transferred
No intrauterine pathology
– Diagnostic HSC
EB
HIS examination
Endometrial culture
Antibiotic therapy
(if necessary)
Control EB
IVF cycle
Group A: patients
with cured CE
(n ¼ 116)
Group B: patients
with
persistent CE
(n ¼ 4)
Group C: patients
without CE
(n ¼ 226)
Clinical
pregnancy
rate
Ongoing
pregnancy/
live birth rate
Miscarriage rate
Note: EB ¼ endometrial biopsy; GnRH-a ¼ GnRH agonist; GnRH-ant ¼ GnRH antagonist; HIS ¼ histology; HSC ¼ hysteroscopy; nr ¼ not reported; OD ¼ oocyte donation; rFSH ¼ recombinant FSH; rhCG ¼ recombinant hCG; U-hCG ¼ urinary hCG.
a Registered trial: identiﬁcation code in square brackets.
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONAscertainment of chronic endometritis diagnosis. One
study (25) was judged at high risk of bias in CE detection
(endometrial biopsy performed during luteal phase). Other
studies were at low risk of bias.
Quality of description of the population. Two studies (23, 26)
were judged at high risk of bias owing to lack of information
about IVF-ET protocols. Other studies provided adequate
information.
Incomplete outcome data. One study provided incomplete
outcome data (23) (Table 2).Synthesis of Results
Treated CE vs. untreated CE (test of cure not performed).
Data from one study (23) did not show a signiﬁcant difference
in OPR/LBR (P¼ .70), CPR (P¼ .66), IR (P¼ .82), and MR
(P¼1.00) in patients with CE receiving antibiotics vs. patients
with CE not receiving therapy.
Cured CE vs. persistent CE. We found a signiﬁcantly higher
OPR/LBR (OR 6.81, 95% CI 2.08–22.24, I 2 ¼ 0%, P¼ .001),
CPR (OR 4.98, 95% CI 1.72–14.43, I2 ¼ 0%, P¼ .003), and IR
(OR 3.24, 95% CI 1.33–7.88, I2 ¼ 0%, P¼ .01) in patients
with cured CE in comparison with those with persistent CE,
with no difference in terms of MR (P¼ .30) (Fig. 1A–1C).
The exclusion of egg donation cycles (from the Tersoglio
et al. study (25)) from pooled analysis did not provideFIGURE 1
A
B
C
Persistent CE vs. cured CE. (A) Ongoing pregnancy/live birth rate; (B) clinic
Vitagliano. Antibiotics for chr endometritis. Fertil Steril 2018.
108statistical changes to OPR/LBR (OR 8.66, 95% CI 2.07–
36.14, I2 ¼ 0%, P¼ .003), CPR (OR 3.42, 95% CI 1.07–10.94,
I2 ¼ 0%, P¼ .04), IR (OR 2.95, 95% CI 1.10–7.95, I2 ¼ 0%,
P¼ .03), and MR (P¼ .20). Sensitivity analysis was not per-
formed owing to minimal inconsistency (I2 ¼ 0%).
Cured CE vs. non-CE. Analysis of 389 patients did not show
any difference between groups in terms of CPR (P¼ .90), OPR/
LBR (P¼ .75), IR (P¼ .93) (Fig. 2A–2C), and MR (P¼ .75). The
exclusion of the study by Tersoglio et al. (25) from aggregate
analysis did not modify OPR/LBR (P¼ .54), CPR (P¼ .81), IR
(P¼ .78), and MR (P¼ .62). Sensitivity analysis (with the
exclusion of Johnston MacAnanny et al. study (22)) yielded
signiﬁcant changes in pooled results, with a signiﬁcant
advantage in patients with cured CE in terms of OPR/LBR
(OR 1.68, 95% CI 1.06–2.67, I2 ¼ 0%, P¼ .03), CPR (OR
1.67, 95% CI 1.06–2.62, I2 ¼ 0%, P¼ .03), and IR (OR 1.78,
95% CI 1.21–2.63, I2 ¼ 0%, P¼ .004), with no difference in
MR (P¼ .27).DISCUSSION
Main Findings
The present systematic review and meta-analysis included a
total of 796 RIF patients from ﬁve observational studies
(22–26). Although patients with cured CE showed higher
OPR/LBR (OR 6.81, P¼ .001), CPR (OR 4.98, P¼ .003), and IRal pregnancy rate; (C) implantation rate. M-H ¼ Mantel-Haenszel.
VOL. 110 NO. 1 / JULY 2018
FIGURE 2
A
B
C
Cured CE vs. non-CE. (A) Ongoing pregnancy/live birth rate; (B) clinical pregnancy rate; (C) implantation rate.
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disease, the only study that compared patients with CE
receiving antibiotics vs. patients not receiving antibiotics
(23) did not observe any difference in terms of CPR, OPR/
LBR, and IR (P¼nonsigniﬁcant). Nevertheless, Yang et al.
(23) did not perform a control biopsy after antibiotic
therapy. Thus, the percentage of patients (among the
antibiotic group) with persistent disease at the time of IVF
was unknown, and this may represent a bias in the
estimation of the beneﬁts from CE treatment. Furthermore,
Yang et al. (23) claimed that antibiotic therapy signiﬁcantly
improved OPR in patients with hysteroscopic signs of CE
(such as mucous hyperemia, edema, and micropolyps). This
may suggest the presence of methodological bias, because
hysteroscopic and histologic ﬁndings are expected to be
nearly correspondent in women with CE, according to other
authors' experience (27).
Moreover, we found no difference in CPR, OPR/LBR, and
IR in patients with cured CE vs. those without CE
(P¼nonsigniﬁcant), with high inconsistency (I2 from 60%
to 79%). The exclusion of egg donation cycles did not modify
pooled results (CPR, OPR/LBR, IR, MR: P¼nonsigniﬁcant).
Data by Johnston-MacAnanny et al. (22) were the main
source of statistical heterogeneity, potentially due to small
sample size (n ¼ 33 patients, of whom 10 with cured CE).
As a matter of fact, other studies (25, 26) (including the
study with better quality and larger size (26)) showed
considerably higher CPR (P¼ .03), OPR/LBR (P¼ .03), and IRVOL. 110 NO. 1 / JULY 2018(P¼ .004) in patients with cured CE. These ﬁndings
potentially suggest that CE is a reversible factor of
infertility, whose recognition and therapy may provide
better chances at subsequent IVF attempts.Strength and Limitations
The present meta-analysis is the ﬁrst evaluating the effects of
CE therapy on IVF outcome. We planned sensitivity and sub-
group analysis to reduce bias related to study heterogeneity,
and we provided unpublished data and details about included
studies. However, our results are considerably limited by the
small number of patients included, heterogeneity in patient
characteristics (including IVF cycles and days for ET
[cleavage-stage vs. blastocyst-stage embryos]), poor method-
ological quality of original studies (no randomized controlled
trial was included), and some concerns about the histologic
diagnosis of CE in two studies (lack of information about
the number and expertise of pathologists (23, 25)).
Moreover, the inconsistent use of endometrial culture, as
well as the variable antibiotic regimens used (type of drug
and duration) may represent additional confounding factors
in estimating the effects of CE therapy on IVF outcome. In
addition, the timing of the ﬁrst biopsy and of the test of
cure varied among studies, potentially generating bias in
the detection of CE. Finally, the lack of genetic testing of
preimplantation embryos did not rule out embryo
aneuploidy as cause for implantation failure.109
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONImplications
Despite recent innovations in ovarian stimulation protocols
(28, 29), reproductive immunology (30, 31), and
reproductive surgery (32, 33), implantation remains the
main limiting factor of IVF success (34, 35). The
implantation process encompasses different stages
(endometrial decidualization, embryo apposition, adhesion,
penetration, and trophoblast invasion) that are ﬁnely
regulated by immune cells and cytokines (36–38). Recent
in vitro studies showed that CE may exert a negative effect
on implantation through impairing decidualization (39) and
altering the expression of proteins involved in endometrial
receptivity (such as cytokines, growth factors, and apoptotic
proteins) (40–42). Accordingly, antibiotic therapy may
eliminate the source of infection, restore normal
endometrial histology, and improve endometrial receptivity
(6, 20). In this respect, the present meta-analysis demonstrates
that such an intriguing hypothesis is reasonable but still not
supported by adequate evidence.
In our opinion, the clariﬁcation of the real impact of CE
(and the potential advantages of CE therapy) on embryo im-
plantation is of critical importance. If our results are
conﬁrmed, CE may represent a new therapeutic target for
women suffering from RIF, with affordable access (diagnosed
through a simple endometrial biopsy and treated by oral an-
tibiotics). Nevertheless, future randomized controlled trials
need to be undertaken to better understand whether CE ther-
apy may really improve IVF outcome in women with RIF.
In conclusion, the present study demonstrates that CE
therapy may improve IVF outcome in patients suffering
from RIF. Notably, the resolution of CE should be conﬁrmed
(at histology) before proceeding with IVF. The body of evi-
dence on this topic is still insufﬁcient to recommend routine
CE screening as intervention to improve CPR and OPR/LBR
in such patients. Future randomized controlled trials are
needed.
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ORIGINAL ARTICLE: ASSISTED REPRODUCTIONEfectos del tratamiento de la endometritis cronica en los resultados de fecundacion in vitro en mujeres con fallo de implantacion recur-
rente: una revision sistematica y meta-analisis
Objetivo: Evaluar el impacto del tratamiento antibiotico de endometritis cronica (CE) sobre el resultado de la fecundacion in vitro.
Dise~no: Revision sistematica y meta-analisis.
Entorno: No aplica.
Paciente (s): Mujeres esteriles con historia de fallo de implantacion recurrente, deﬁnido como dos o mas transferencias embrionarias
(ETs), sometidas a uno o mas ciclos de FIV.
Intervencion (s): La revision fue registrada en PROSPERO (CRD42017062494) antes del comienzo de la busqueda bibliograﬁca. Los
estudios observacionales se identiﬁcaron mediante la busqueda de bases de datos electronicas. Se incluyeron las siguientes compara-
ciones: mujeres con CE tratadas con antibioticos vs controles sin tratamiento; mujeres con CE curada vs. mujeres con endometritis per-
sistente; y mujeres con CE curada vs. mujeres con histología endometrial normal (negativa para CE). El resumen de las medidas se
informo como odds ratio (OR) con un 95% de intervalo de conﬁanza (CI).
Principales Medidas de Resultado: tasa de gestacion clínica (CPR), tasa de embarazo evolutivo/tasa de nacido vivo (OPR/LBR), tasa de
implantacion (IR) y tasa de aborto.
Resultado (s): Se incluyeron un total de 796 pacientes (procedentes de cinco estudios). Las mujeres que recibieron antibioticos (sin la
conﬁrmacion histologica de CE curada) no mostraron ninguna ventaja comparadas con controles no tratadas (OPR/LBR, CPR e IR). Pa-
cientes con CE curadamostraronmas alta OPR/LBR (OR 6.81), CPR (OR 4.02) e IR (OR 3.24) comparadas con pacientes con CE persistente.
El resultado de fecundacion in vitro fue comparable entre mujeres con CE curada y aquellas sin CE (OPR/LBR, CPR, e IR). La tasa de
aborto no fue signiﬁcativamente diferente entre grupos.
Conclusion (s): El tratamiento de endometritis cronica puede mejorar los resultados de FIV en pacientes que padecen fallo de im-
plantacion recurrente. Siempre debería conﬁrmarse la resolucion de CE mediante biopsia antes del inicio de una FIV.112 VOL. 110 NO. 1 / JULY 2018
SUPPLEMENTAL FIGURE 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses ﬂow diagram.
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